ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$185.16 |
| 52 Week High | US$186.85 |
| 52 Week Low | US$135.85 |
| Beta | 0.62 |
| 11 Month Change | 8.19% |
| 3 Month Change | 16.00% |
| 1 Year Change | 22.74% |
| 33 Year Change | 59.21% |
| 5 Year Change | 183.34% |
| Change since IPO | 429.03% |
Recent News & Updates
Recent updates
AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)
Jun 28
AbbVie: 5 Reasons That Make A Buy Case
Jun 18Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
May 29Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly
May 21AbbVie's Q1: Positive Surprise
Apr 26AbbVie: Great To Be Proven Wrong - Still Not A Buy
Apr 14AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
Apr 08AbbVie: Strong Cash Flow Growth Fuels Dividend Growth
Mar 08Shareholder Returns
| ABBV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.5% | 4.2% | -0.6% |
| 1Y | 22.7% | 15.7% | 17.3% |
Return vs Industry: ABBV exceeded the US Biotechs industry which returned 15.7% over the past year.
Return vs Market: ABBV exceeded the US Market which returned 17.3% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 3.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | US$321.69b |
| Earnings (TTM) | US$5.30b |
| Revenue (TTM) | US$55.00b |
61.7x
P/E Ratio5.9x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$55.00b |
| Cost of Revenue | US$16.77b |
| Gross Profit | US$38.23b |
| Other Expenses | US$32.94b |
| Earnings | US$5.30b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.00 |
| Gross Margin | 69.52% |
| Net Profit Margin | 9.63% |
| Debt/Equity Ratio | 924.1% |
How did ABBV perform over the long term?
See historical performance and comparison